Cancer Clinical Investigation

Search results

• Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

  Galsky, M.

  1/04/24

  1 item of Media coverage

  Press/Media

• 08:16 EDT Natera launches Alliance A032103 utilizing Signatera MRD test for MIUC

  Galsky, M.

  1/04/24

  1 item of Media coverage

  Press/Media

• Researchers from Icahn School of Medicine at Mount Sinai Publish New Studies and Findings in the Area of Immunotherapy (Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to ...)

  Fred Hirsch, Fred Hirsch & Diego de Miguel Perez

  1/04/24

  1 item of Media coverage

  Press/Media

• Data on Kidney Cancer Described by Researchers at Icahn School of Medicine at Mount Sinai (Characterization of Renal Masses With Mri-based Radiomics: Assessment of Inter-package and Inter-observer Reproducibility In a Prospective Pilot Study)

  Badani, K., Lewis, S., Taouli, B., Bane, O. & Horowitz, A.

  1/04/24

  1 item of Media coverage

  Press/Media

• Onconova Therapeutics Compendium - A Snapshot as of March 31, 2024

  Reddy, E. P.

  1/04/24

  2 items of Media coverage

  Press/Media

• Onconova Therapeutics Compendium - A Snapshot as of March 31, 2024

  Reddy, E. P.

  1/04/24

  1 item of Media coverage

  Press/Media

• EDAP TMS S.A. (NASDAQ:EDAP) Q4 2023 Earnings Call Transcript

  Tewari, A.

  29/03/24

  3 items of Media coverage

  Press/Media

• Dr Galsky on the FDA Approval of Nivolumab Plus Chemotherapy in Urothelial Carcinoma

  Galsky, M.

  29/03/24

  1 item of Media coverage

  Press/Media

• Studies from Shanghai Jiao Tong University Add New Findings in the Area of Balloon Catheter (Drug-coated Balloon Angioplasty for Dysfunctional Arteriovenous Hemodialysis Fistulae)

  Wang, P.

  28/03/24

  1 item of Media coverage

  Press/Media

• Reports from Icahn School of Medicine at Mount Sinai Provide New Insights into Myelofibrosis (Real-world Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes)

  Mascarenhas, J.

  26/03/24

  1 item of Media coverage

  Press/Media

• Sun-obsessed Gen Z is behind the Big Apple’s tanning craze — with some even ‘addicted’ to bronzing: ‘Nobody wants to be pale’

  Gulati, N.

  26/03/24

  2 items of Media coverage

  Press/Media

• Research Conducted at Washington University Has Provided New Information about Breast Cancer (Endocrine-sensitive Disease Rate In Postmenopausal Patients With Estrogen Receptor-rich/erbb2-negative Breast Cancer Receiving Neoadjuvant ...)

  Tiersten, A.

  21/03/24

  1 item of Media coverage

  Press/Media

• Non-surgical Options in Bladder Cancer

  Galsky, M.

  21/03/24

  1 item of Media coverage

  Press/Media

• Researchers from Johns Hopkins University School of Medicine Detail Research in Ductal Carcinoma (Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study)

  Sparano, J.

  20/03/24

  1 item of Media coverage

  Press/Media

• Researchers from Icahn School of Medicine at Mount Sinai Report New Studies and Findings in the Area of Biomarkers (The Utility of Biomarkers In Acute Gvhd Prognostication)

  Levine, J., Etra, A. & Akahoshi, Y.

  19/03/24

  1 item of Media coverage

  Press/Media

• A Mount Sinai-Led Study Shows Early Success of a Novel Drug in Treating a Rare and Chronic Blood Cancer

  Ginzburg, Y., Hoffman, R. & Kremyanskaya, M.

  19/03/24

  1 item of Media coverage

  Press/Media

• Game’s afoot in bladder cancer research

  Sfakianos, J. & Galsky, M.

  18/03/24

  1 item of Media coverage

  Press/Media

• Central Hospital of Wuhan Researchers Detail Findings in Deafness [The clinical and genetic characteristics of maternally inherited diabetes and deafness (MIDD) with mitochondrial m.3243A > G mutation: A 10-year follow-up observation study and ...]

  Wang, P.

  18/03/24

  1 item of Media coverage

  Press/Media

• Revisit the OncLive On Air Episodes From February 2024

  Galsky, M.

  18/03/24

  1 item of Media coverage

  Press/Media

• U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma

  Jagannath, S.

  15/03/24 → 16/03/24

  27 items of Media coverage

  Press/Media

• U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma

  Jagannath, S.

  15/03/24

  1 item of Media coverage

  Press/Media

• Johnson & Johnson: U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma

  Jagannath, S.

  15/03/24

  1 item of Media coverage

  Press/Media

• The 1st International Symposium on Cancer Immunology and Immunotherapy

  Merad, M. & Marron, T.

  13/03/24

  1 item of Media coverage

  Press/Media

• University of Colorado School of Medicine Researchers Update Understanding of Radiation Therapy (Clinical and Dosimetric Impact of 2D kV Motion Monitoring and Intervention in Liver Stereotactic Body Radiation Therapy)

  Goodman, K.

  12/03/24

  1 item of Media coverage

  Press/Media

• Reports from Icahn School of Medicine at Mount Sinai Provide New Insights into Cancer [Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a Cyp3a4 Substrate, Plus Cyp3a4-interacting Antiretroviral Therapy In People Living With Hiv and ...]

  Sparano, J.

  11/03/24

  1 item of Media coverage

  Press/Media